0 XP   0   0   0

XORTX Therapeutics Inc










Financial Health of Xortx




Comparing to competitors in the Biotechnology industry




  Industry Rankings  


XORTX Therapeutics Inc
Buy, Hold or Sell?

Should you buy, hold or sell Xortx?

I guess you are interested in XORTX Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

Let's analyse Xortx

Let's start. I'm going to help you getting a better view of XORTX Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

  1. Company's Financial Health
    A deep dive into the books. How are the numbers doing? Is XORTX Therapeutics Inc even making a profit? Is the company skyrocketing? Or is it sinking like the Titanic. The trend is your friend.
  2. Market Valuation
    Finally, you now have an insight of how XORTX Therapeutics Inc is doing in the market. If the company is worth buying. The latest step is to find out how other investors value XORTX Therapeutics Inc. The closing price on 2022-12-02 was $0.93 per share. Is the company over- or underpriced?
  3. Key Performance Indicators
    A total overlook on how the company is doing. Based on the (trends in) the key performance indicators.
XORTX Therapeutics Inc Daily Candlestick Chart

Summary

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

1.1. Profitability of XORTX Therapeutics Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Xortx earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Xortx to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of XORTX Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--223.6%+223.6%
TTM--281.7%+281.7%
YOY--344.8%+344.8%
5Y--450.1%+450.1%
10Y--541.0%+541.0%
1.1.2. Return on Assets

Shows how efficient Xortx is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Xortx to the Biotechnology industry mean.
  • -9.9% Return on Assets means that Xortx generated $-0.10 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of XORTX Therapeutics Inc:

  • The MRQ is -9.9%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -23.5%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-9.9%TTM-23.5%+13.6%
TTM-23.5%YOY-16.3%-7.2%
TTM-23.5%5Y-19.9%-3.6%
5Y-19.9%10Y-19.9%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-9.9%-9.9%+0.0%
TTM-23.5%-8.9%-14.6%
YOY-16.3%-9.3%-7.0%
5Y-19.9%-11.7%-8.2%
10Y-19.9%-12.7%-7.2%
1.1.3. Return on Equity

Shows how efficient Xortx is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Xortx to the Biotechnology industry mean.
  • -12.9% Return on Equity means Xortx generated $-0.13 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of XORTX Therapeutics Inc:

  • The MRQ is -12.9%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is 4.0%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ-12.9%TTM4.0%-16.9%
TTM4.0%YOY-32.7%+36.6%
TTM4.0%5Y-14.4%+18.3%
5Y-14.4%10Y-14.4%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-12.9%-12.0%-0.9%
TTM4.0%-11.5%+15.5%
YOY-32.7%-10.8%-21.9%
5Y-14.4%-14.2%-0.2%
10Y-14.4%-15.2%+0.8%

1.2. Operating Efficiency of XORTX Therapeutics Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Xortx is operating .

  • Measures how much profit Xortx makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Xortx to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of XORTX Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--207.3%+207.3%
TTM--271.0%+271.0%
YOY--325.9%+325.9%
5Y--454.0%+454.0%
10Y--537.1%+537.1%
1.2.2. Operating Ratio

Measures how efficient Xortx is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of XORTX Therapeutics Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.871-2.871
TTM-3.504-3.504
YOY-3.604-3.604
5Y-5.132-5.132
10Y-6.371-6.371

1.3. Liquidity of XORTX Therapeutics Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Xortx is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 14.09 means the company has $14.09 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of XORTX Therapeutics Inc:

  • The MRQ is 14.085. The company is very able to pay all its short-term debts. +2
  • The TTM is 15.716. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ14.085TTM15.716-1.631
TTM15.716YOY1.961+13.755
TTM15.7165Y8.839+6.878
5Y8.83910Y8.8390.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ14.0855.117+8.968
TTM15.7165.755+9.961
YOY1.9615.854-3.893
5Y8.8396.511+2.328
10Y8.8396.222+2.617
1.3.2. Quick Ratio

Measures if Xortx is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Xortx to the Biotechnology industry mean.
  • A Quick Ratio of 0.25 means the company can pay off $0.25 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of XORTX Therapeutics Inc:

  • The MRQ is 0.251. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.127. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.251TTM0.127+0.124
TTM0.127YOY0.010+0.117
TTM0.1275Y0.068+0.059
5Y0.06810Y0.0680.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2514.284-4.033
TTM0.1274.664-4.537
YOY0.0104.787-4.777
5Y0.0685.218-5.150
10Y0.0685.182-5.114

1.4. Solvency of XORTX Therapeutics Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Xortx assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Xortx to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.24 means that Xortx assets are financed with 23.7% credit (debt) and the remaining percentage (100% - 23.7%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of XORTX Therapeutics Inc:

  • The MRQ is 0.237. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.573. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.237TTM0.573-0.336
TTM0.573YOY0.488+0.085
TTM0.5735Y0.530+0.043
5Y0.53010Y0.5300.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2370.278-0.041
TTM0.5730.277+0.296
YOY0.4880.306+0.182
5Y0.5300.367+0.163
10Y0.5300.403+0.127
1.4.2. Debt to Equity Ratio

Measures if Xortx is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Xortx to the Biotechnology industry mean.
  • A Debt to Equity ratio of 31.0% means that company has $0.31 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of XORTX Therapeutics Inc:

  • The MRQ is 0.310. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.251. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.310TTM0.251+0.060
TTM0.251YOY1.001-0.750
TTM0.2515Y0.626-0.375
5Y0.62610Y0.6260.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3100.315-0.005
TTM0.2510.317-0.066
YOY1.0010.319+0.682
5Y0.6260.403+0.223
10Y0.6260.462+0.164

2. Market Valuation of XORTX Therapeutics Inc

2. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Xortx generates.

  • Above 15 is considered overpriced but always compare Xortx to the Biotechnology industry mean.
  • A PE ratio of -17.28 means the investor is paying $-17.28 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of XORTX Therapeutics Inc:

  • The EOD is -11.394. Company is losing money. -2
  • The MRQ is -17.275. Company is losing money. -2
  • The TTM is -8.760. Company is losing money. -2
Trends
Current periodCompared to+/- 
EOD-11.394MRQ-17.275+5.881
MRQ-17.275TTM-8.760-8.515
TTM-8.760YOY-5.812-2.948
TTM-8.7605Y-7.286-1.474
5Y-7.28610Y-7.2860.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-11.394-8.986-2.408
MRQ-17.275-9.792-7.483
TTM-8.760-16.243+7.483
YOY-5.812-20.876+15.064
5Y-7.286-16.665+9.379
10Y-7.286-14.732+7.446
2.2. Price Earnings to Growth Ratio

Measures the predicted future growth of Xortx.

  • Lower is better.
  • A PEG ratio of 1 means the market price of the stock and the expected future earnings are on par.

Let's take a look of the Price Earnings to Growth Ratio trends of XORTX Therapeutics Inc:

  • The MRQ is -14.832. Very Bad. -2
  • The TTM is 0.464. Very good. +2
Trends
Current periodCompared to+/- 
MRQ-14.832TTM0.464-15.296
TTM0.464YOY27.095-26.631
TTM0.4645Y11.878-11.413
5Y11.87810Y11.8780.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-14.832-0.032-14.800
TTM0.4640.004+0.460
YOY27.0950.016+27.079
5Y11.8780.006+11.872
10Y11.8780.003+11.875

2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Xortx is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 2.23 means the investor is paying $2.23 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of XORTX Therapeutics Inc:

  • The EOD is 1.472. Good. +1
  • The MRQ is 2.231. Good. +1
  • The TTM is -3.612. Bad. Book ratio is negative. -2
Trends
Current periodCompared to+/- 
EOD1.472MRQ2.231-0.760
MRQ2.231TTM-3.612+5.843
TTM-3.612YOY1.187-4.798
TTM-3.6125Y-1.212-2.399
5Y-1.21210Y-1.2120.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.4721.835-0.363
MRQ2.2312.006+0.225
TTM-3.6122.774-6.386
YOY1.1873.453-2.266
5Y-1.2122.713-3.925
10Y-1.2122.402-3.614
2. Total Gains per Share

2.4. Latest News of XORTX Therapeutics Inc

Does XORTX Therapeutics Inc still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from XORTX Therapeutics Inc to keep up to date. Note: the news is often already included in the price.

DateTitleRead
2022-11-25
23:45
XORTX Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price DeficiencyRead

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of XORTX Therapeutics Inc.

3.1. Institutions holding XORTX Therapeutics Inc

Institutions are holding 5.62% of the shares of XORTX Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2022-06-30CIBC World Markets Inc.0.20790.000127000450020
2022-06-30UBS Group AG0.043905701199753.9147
2022-06-30Royal Bank of Canada0.0070915-779-45.9858
2022-06-30Bank of America Corp00200
2022-06-30Susquehanna International Group, LLP000-29214-100
2022-06-30Virtu Financial LLC000-12015-100
Total 0.25880.000133618-35511-105.6%

4. Summary

4.1. Key Performance Indicators

The key performance indicators of XORTX Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.0600.115-152%0.043-239%0.079-176%0.079-176%
Book Value Growth---0.094-0.218+131%0.088-208%-0.087-8%-0.087-8%
Book Value Per Share--0.6320.492+28%0.125+404%0.309+105%0.309+105%
Book Value Per Share Growth---0.094-0.218+131%0.088-208%-0.087-8%-0.087-8%
Current Ratio--14.08515.716-10%1.961+618%8.839+59%8.839+59%
Debt To Asset Ratio--0.2370.573-59%0.488-51%0.530-55%0.530-55%
Debt To Equity Ratio--0.3100.251+24%1.001-69%0.626-50%0.626-50%
Dividend Per Share----0%-0%-0%-0%
Eps---0.082-0.055-33%-0.042-48%-0.049-40%-0.049-40%
Eps Growth--1.165-0.387+133%2.699-57%0.936+24%0.936+24%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Net Profit Margin----0%-0%-0%-0%
Operating Margin----0%-0%-0%-0%
Operating Ratio----0%-0%-0%-0%
Pb Ratio1.472-52%2.231-3.612+262%1.187+88%-1.212+154%-1.212+154%
Pe Ratio-11.394+34%-17.275-8.760-49%-5.812-66%-7.286-58%-7.286-58%
Peg Ratio---14.8320.464-3294%27.095-155%11.878-225%11.878-225%
Price Per Share0.930-52%1.4102.549-45%0.130+984%1.339+5%1.339+5%
Price To Total Gains Ratio-15.582+34%-23.624-11.329-52%-4.953-79%-8.141-66%-8.141-66%
Profit Growth--116.475-38.676+133%269.883-57%93.564+24%93.564+24%
Quick Ratio--0.2510.127+97%0.010+2516%0.068+267%0.068+267%
Return On Assets---0.099-0.235+138%-0.163+65%-0.199+101%-0.199+101%
Return On Equity---0.1290.040-425%-0.327+153%-0.144+11%-0.144+11%
Total Gains Per Share---0.0600.115-152%0.043-239%0.079-176%0.079-176%
Total Gains Per Share Growth--1.886-1.255+167%-6.507+445%-3.506+286%-3.506+286%
Usd Book Value--9093692.3277082223.992+28%1804293.656+404%4443258.824+105%4443258.824+105%
Usd Book Value Change Per Share---0.0600.115-152%0.043-239%0.079-176%0.079-176%
Usd Book Value Per Share--0.6320.492+28%0.125+404%0.309+105%0.309+105%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.082-0.055-33%-0.042-48%-0.049-40%-0.049-40%
Usd Price Per Share0.930-52%1.4102.549-45%0.130+984%1.339+5%1.339+5%
Usd Profit---1174479.043-791905.360-33%-607070.911-48%-699488.136-40%-699488.136-40%
Usd Revenue----0%-0%-0%-0%
Usd Total Gains Per Share---0.0600.115-152%0.043-239%0.079-176%0.079-176%
 EOD+3 -2MRQTTM+14 -13YOY+13 -145Y+15 -1210Y+15 -12

4.2. Fundamental Score

Let's check the fundamental score of XORTX Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-11.394
Price to Book Ratio (EOD)Between0-11.472
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.251
Current Ratio (MRQ)Greater than114.085
Debt to Asset Ratio (MRQ)Less than10.237
Debt to Equity Ratio (MRQ)Less than10.310
Return on Equity (MRQ)Greater than0.15-0.129
Return on Assets (MRQ)Greater than0.05-0.099
Total3/10 (30.0%)

4.3. Technical Score

Let's check the technical score of XORTX Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose0.930
Total0/1 (0.0%)



Latest Balance Sheet

Balance Sheet of 2022-06-30. Currency in CAD. All numbers in thousands.

Summary
Total Assets16,045
Total Liabilities3,801
Total Stockholder Equity12,244
 As reported
Total Liabilities 3,801
Total Stockholder Equity+ 12,244
Total Assets = 16,045

Assets

Total Assets16,045
Total Current Assets14,014
Long-term Assets14,014
Total Current Assets
Cash And Cash Equivalents 13,421
Net Receivables 249
Total Current Assets  (as reported)14,014
Total Current Assets  (calculated)13,670
+/- 344
Long-term Assets
Property Plant Equipment 167
Intangible Assets 259
Other Assets 1,606
Long-term Assets  (as reported)2,032
Long-term Assets  (calculated)2,032
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities995
Long-term Liabilities2,806
Total Stockholder Equity12,244
Total Current Liabilities
Accounts payable 743
Total Current Liabilities  (as reported)995
Total Current Liabilities  (calculated)743
+/- 252
Long-term Liabilities
Other Liabilities 2,745
Long-term Liabilities  (as reported)2,806
Long-term Liabilities  (calculated)2,745
+/- 61
Total Stockholder Equity
Common Stock20,009
Retained Earnings -14,695
Other Stockholders Equity 6,930
Total Stockholder Equity (as reported)12,244
Total Stockholder Equity (calculated)12,244
+/-0
Other
Capital Stock20,009
Common Stock Shares Outstanding 12,990
Net Invested Capital 12,244
Net Tangible Assets 11,985
Net Working Capital 13,019



Balance Sheet

Currency in CAD. All numbers in thousands.

 Trend2022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-30
> Total Assets 
2,664
2,290
8,248
7,333
7,833
22,036
18,441
16,045
16,04518,44122,0367,8337,3338,2482,2902,664
   > Total Current Assets 
2,396
2,056
8,018
7,097
7,589
20,173
16,580
14,014
14,01416,58020,1737,5897,0978,0182,0562,396
       Cash And Cash Equivalents 
189
171
6,044
5,149
4,998
18,851
15,509
13,421
13,42115,50918,8514,9985,1496,044171189
       Net Receivables 
16
14
11
23
22
52
156
249
249156522223111416
       Other Current Assets 
2,106
1,826
1,826
1,826
2,448
0
220
0
022002,4481,8261,8261,8262,106
   > Long-term Assets 
269
234
230
236
244
1,863
1,861
2,032
2,0321,8611,863244236230234269
       Property Plant Equipment 
0
0
0
0
0
0
0
167
1670000000
       Intangible Assets 
269
234
230
236
244
256
255
259
259255256244236230234269
       Other Assets 
0
0
0
0
0
1,606
1,606
1,606
1,6061,6061,60600000
> Total Liabilities 
995
1,034
4,777
4,013
12,072
5,298
5,041
3,801
3,8015,0415,29812,0724,0134,7771,034995
   > Total Current Liabilities 
995
1,034
4,777
4,013
12,072
701
856
995
99585670112,0724,0134,7771,034995
       Accounts payable 
358
390
26
359
641
411
732
743
74373241164135926390358
       Other Current Liabilities 
100
0
4,247
3,592
11,355
4,597
0
0
004,59711,3553,5924,2470100
   > Long-term Liabilities 
0
0
0
0
0
4,597
4,185
2,806
2,8064,1854,59700000
       Other Liabilities 
0
0
0
0
0
4,597
4,185
2,745
2,7454,1854,59700000
> Total Stockholder Equity
1,670
1,256
3,471
3,320
-4,239
16,738
13,401
12,244
12,24413,40116,738-4,2393,3203,4711,2561,670
   Common Stock
8,350
8,258
12,278
12,255
13,057
20,009
20,009
20,009
20,00920,00920,00913,05712,25512,2788,2588,350
   Retained Earnings -14,695-13,114-9,690-18,785-10,430-10,211-8,038-7,590
   Capital Surplus 00000000
   Treasury Stock00000000
   Other Stockholders Equity 
911
1,036
1,404
1,495
1,489
6,419
6,505
6,930
6,9306,5056,4191,4891,4951,4041,036911



Balance Sheet

Currency in CAD. All numbers in thousands.




Cash Flow

Currency in CAD. All numbers in thousands.




Income Statement

Currency in CAD. All numbers in thousands.


Latest Income Statement (annual, 2021-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue--
Gross Profit-0
 
Operating Income (+$)
Gross Profit-
Operating Expense-3,650
Operating Income-3,650-3,650
 
Operating Expense (+$)
Research Development853
Selling General Administrative2,779
Selling And Marketing Expenses-
Operating Expense3,6503,632
 
Net Interest Income (+$)
Interest Income-
Interest Expense-6
Net Interest Income-1,629-6
 
Pretax Income (+$)
Operating Income-3,650
Net Interest Income-1,629
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-1,652-7,276
EBIT - interestExpense = -2,900
-1,652
-1,647
Interest Expense6
Earnings Before Interest and Taxes (ebit)-2,894-1,647
Earnings Before Interest and Taxes (ebitda)-1,629
 
After tax Income (+$)
Income Before Tax-1,652
Tax Provision--
Net Income From Continuing Ops-1,652-1,652
Net Income-1,652
Net Income Applicable To Common Shares-1,652
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net3,6271,629
 

Comments

Join the conversation.

Leave a comment

Stay informed with my latest content.

Subscribe to my newsletter and receive an email as soon as I add content to PenkeTrading.com.


By clicking Register, you agree to the General Terms and Conditions.
Penke's Market Notifications
ACC.BSE
5 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of ACC.BSE.

ACC.BSE Daily Candlestick Chart
VRL.BSE
15 minutes ago

I found you a Golden Cross on the daily chart of VRL.BSE.

VRL.BSE Daily Candlestick Chart
CANDOUR.BSE
15 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of CANDOUR.BSE.

CANDOUR.BSE Daily Candlestick Chart
VMUK.LSE
26 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of VMUK.LSE.

VMUK.LSE Daily Candlestick Chart
YGEN.LSE
27 minutes ago

I found you a STOCH Bullish Reversal Divergence on the daily chart of YGEN.LSE.

YGEN.LSE Daily Candlestick Chart
GROC.LSE
27 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of GROC.LSE.

GROC.LSE Daily Candlestick Chart
HMAD.LSE
28 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of HMAD.LSE.

HMAD.LSE Daily Candlestick Chart
XSLR.LSE
28 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of XSLR.LSE.

XSLR.LSE Daily Candlestick Chart
0HA0.LSE
29 minutes ago

I found you a Golden Cross on the daily chart of 0HA0.LSE.

0HA0.LSE Daily Candlestick Chart
APAX.LSE
30 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of APAX.LSE.

APAX.LSE Daily Candlestick Chart
PDL.LSE
30 minutes ago

I found you a Death Cross on the daily chart of PDL.LSE.

PDL.LSE Daily Candlestick Chart
XZEZ.LSE
31 minutes ago

I found you a Golden Cross on the daily chart of XZEZ.LSE.

XZEZ.LSE Daily Candlestick Chart
XZBD.LSE
31 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of XZBD.LSE.

XZBD.LSE Daily Candlestick Chart
VGPA.LSE
31 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of VGPA.LSE.

VGPA.LSE Daily Candlestick Chart
HXEM.TO
32 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of HXEM.TO.

HXEM.TO Daily Candlestick Chart
4I1.XETRA
32 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of 4I1.XETRA.

4I1.XETRA Daily Candlestick Chart
KTN.XETRA
32 minutes ago

I found you a Golden Cross on the daily chart of KTN.XETRA.

KTN.XETRA Daily Candlestick Chart
XNZE.XETRA
32 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of XNZE.XETRA.

XNZE.XETRA Daily Candlestick Chart
BIKE.XETRA
32 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of BIKE.XETRA.

BIKE.XETRA Daily Candlestick Chart
GTK.XETRA
33 minutes ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of GTK.XETRA.

GTK.XETRA Daily Candlestick Chart
BSL.XETRA
33 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of BSL.XETRA.

BSL.XETRA Daily Candlestick Chart
UIM1.XETRA
35 minutes ago

I found you a Golden Cross on the daily chart of UIM1.XETRA.

UIM1.XETRA Daily Candlestick Chart
PGN.XETRA
38 minutes ago

I found you a STOCH Bearish Reversal Divergence on the daily chart of PGN.XETRA.

PGN.XETRA Daily Candlestick Chart
LHA.XETRA
38 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of LHA.XETRA.

LHA.XETRA Daily Candlestick Chart